Details of the Drug

General Information of Drug (ID: DMD3C21)

Drug Name

GBT021601

Synonyms

Osivelotor; GBT-601; GBT021601; GBT-021601; 2417955-18-9; osivelotor [INN]; 2-hydroxy-6-({(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl}methoxy)benzaldehyde; 2-hydroxy-6-[[(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl]methoxy]benzaldehyde; SCHEMBL21957946; GTPL12856; UK749B4S16; example 8 [US20210047309]; HY-148788; CS-0641066; 2-hydroxy-6-{[(3S)-4-{[2-(2-hydroxyethyl)pyridin-3- yl]carbonyl}morpholin-3-yl]methoxy}benzaldehyde

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2/3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C20H22N2O6
Canonical SMILES: C1COCC(N1C(=O)C2=C(N=CC=C2)CCO)COC3=CC=CC(=C3C=O)O
InChI: InChI=1S/C20H22N2O6/c23-9-6-17-15(3-2-7-21-17)20(26)22-8-10-27-12-14(22)13-28-19-5-1-4-18(25)16(19)11-24/h1-5,7,11,14,23,25H,6,8-10,12-13H2/t14-/m0/s1
InChIKey: NIWBSQAKKNNWBT-AWEZNQCLSA-N

Cross-matching ID

PubChem CID: 146567655
TTD ID: DWR4I7

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05632354) An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial. U.S.National Institutes of Health.
2	GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.